HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Mulls Putting Cash Behind Interest In Buying L’Oreal’s Shares

This article was originally published in The Tan Sheet

Executive Summary

Sanofi has the cash to buy back about $12 billion of its shares currently owned by beauty firm L’Oreal, if those shares were up for sale, Sanofi CEO Viehbacher says. L’Oreal CEO Agon suggested in recent earnings call that the firm could seek cash for future deals through the sale of its 9% stake in Sanofi.

You may also be interested in...



Sanofi Names Regenauer Global OTC Head, Underscores Consumer Focus

Sanofi-Aventis further highlights its consumer health focus by naming Hans Regenauer to head its global OTC business as the firm works to close its acquisition of OTC and personal care firm Chattem

With $1.9 Bil. Bid For Chattem, Sanofi Knocks On Door To U.S. OTC Market

With its $1.9 billion bid for personal-care and over-the-counter drug manufacturer Chattem, French pharmaceutical giant Sanofi-Aventis stands to gain a toehold in the sizeable U.S. consumer health sector and beef up its presence in emerging markets

L’Oréal Partners With Microalgae Biotech For New Cosmetic Actives

French firms L’Oréal and Microphyt partner to drive development of cosmetic solutions based on the latter’s patented, low-carbon process for cultivating microalgae. Already, Microphyt markets three cosmetic ingredients based on microalgae bioactives for enhanced skin vitality and resilience.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS124521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel